Loading...
Please wait, while we are loading the content...
Similar Documents
Safety and Efficacy of Initiating Highly Active Antiretroviral Therapy in an Integrated Antenatal and HIV Clinic in Johannesburg, South Africa
| Content Provider | Scilit |
|---|---|
| Author | Black, Vivian Hoffman, Risa M. Sugar, Catherine A. Menon, Priya Venter, Francois Currier, Judith S. Rees, Helen |
| Copyright Year | 2008 |
| Description | Journal: JAIDS Journal of Acquired Immune Deficiency Syndromes Objective: To describe the safety and efficacy of highly active antiretroviral therapy (HAART) in pregnant women treated in an integrated antiretroviral antenatal clinic (ANC ARV). Methods: A retrospective analysis was performed on patients attending the ANC ARV from August 2004 through February 2007. Results: Data were collected on 689 treatment-naive pregnant women initiated on HAART. The mean age was 29.2 years. The mean baseline CD4+ count was 154 cells per microliter, and mean baseline HIV viral load was 101,561 copies per milliliter. Tuberculosis was the most prevalent presenting opportunistic infection (7.7%). Stavudine, lamivudine, and nevirapine were initiated in 82% of women with the most frequent adverse drug reaction being nevirapine-associated skin rash (3.5%). Mean gestational age at HAART initiation was 27 weeks. Among women with follow-up data, 80% gained 50 or more CD4 cells per microliter and 80.5% achieved viral suppression to <1000 copies per milliliter. Of 302 mother-infant pairs who completed postnatal follow-up, the HIV transmission rate was 5%. In women who received more than 7 weeks of HAART during pregnancy, transmission was 0.3%. Conclusions: Within the ANC ARV program, initiating pregnant women on HAART was feasible, safe, and effective. Advanced gestational age at treatment initiation and loss to follow-up emerge as important challenges in this population. |
| Related Links | http://europepmc.org/articles/pmc2893046?pdf=render https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893046/pdf |
| Ending Page | 281 |
| Page Count | 6 |
| Starting Page | 276 |
| ISSN | 15254135 |
| e-ISSN | 10779450 |
| DOI | 10.1097/qai.0b013e318189a769 |
| Journal | JAIDS Journal of Acquired Immune Deficiency Syndromes |
| Issue Number | 3 |
| Volume Number | 49 |
| Language | English |
| Publisher | Ovid Technologies (Wolters Kluwer Health) |
| Publisher Date | 2008-11-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: JAIDS Journal of Acquired Immune Deficiency Syndromes High Active Antiretroviral Therapy (haart) Prevention of Mother-to-child Transmission (pmtct) |
| Content Type | Text |
| Resource Type | Article |
| Subject | Infectious Diseases Pharmacology (medical) |
